Boston Red Sox principal owner John Henry made a late-round investment in Cambridge, Mass., drugmaker Sirtris Pharmaceuticals Inc., leading The Boston Globe to second guess the hedge funder. Henry made the $20 million bet shortly before the three-year old startup filed March 1 for a $60 million initial public offering. The firm is developing drugs to treat metabolic disease such as type-2 diabetes by mimicking the effects of calorie restriction in aging. Other major shareholders include Polaris Venture Partners of Waltham, Mass., Boston's TVM Capital Corp. and Peter Lynch. However, its Henry's investment that drew the interest of Globe business columnist Steven Syre. The fact that the Globe is questioning the IPO market is not shocking, but second guessing a succesful dealmaker responsible for bringing a World Series win to Boston after 86 years is shocking.—Matthew Wurtzel
See story from The Boston Globe
See earlier story from TheDeal.com
Continue reading below
